United Therapeutics
UTHR
303 hedge funds and large institutions have $4.08B invested in United Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 94 increasing their positions, 100 reducing their positions, and 63 closing their positions.
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
64% more call options, than puts
Call options by funds: $24.1M | Put options by funds: $14.6M
12% more capital invested
Capital invested by funds: $3.63B → $4.08B (+$453M)
4.16% more ownership
Funds ownership: 93.94% → 98.11% (+4.2%)
6% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 100
5% less funds holding
Funds holding: 320 → 303 (-17)
21% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$55M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$51M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$41M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.7M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$48.8M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$39.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$34.7M |
| 4 |
Millennium Management
New York
|
-$25M |
| 5 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$21.5M |
UTHR Hedge Fund Activity: Q1 2020 in Review
303 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2020, worth a combined $4.08B — up 12% from $3.63B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of UTHR and 50 opened new positions — a net loss of 13 holders — while 100 trimmed existing stakes and 94 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $55M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $48.8M sold.
- 303 institutional investors held United Therapeutics (UTHR) as of Q1 2020, down from 320 in Q4 2019.
- Funds reported $4.08B of United Therapeutics stock for Q1 2020, up 12% quarter-over-quarter.
- 50 funds opened new United Therapeutics positions in Q1 2020 and 63 closed out, a net change of -13 holders.
- The largest United Therapeutics buyer in Q1 2020 was Point72 Asset Management, an estimated $55M added.
- The largest United Therapeutics seller in Q1 2020 was Arrowstreet Capital, an estimated $48.8M sold.
Based on aggregated 13F filings for Q1 2020.